Nirogy Therapeutics, Inc.

High prevalence of cancer, coupled with the increasing demand for targeted therapy drugs will drive oncology small molecule drugs sales Fact.MR, New York: Fact.MR’s recent study has projected the global oncology small molecule drugs market to grow at a healthy pace through 2021. Rising prevalence of cancer and improving availability of oral small molecule drugs for cancer treatment are expected to drive the market. According to the study, increasing focus of biopharmaceutical and pharmaceutical companies on developing targeted small molecule therapy drugs is expected to spur the market growth. Soaring research and development (R&D) activities for targeted therapies such as hormone therapies, signal transduction inhibitors and immunotherapies among research centers are accelerating the growth of oncology small molecule drugs market. Additionally, fast clinical trials and approval by the U.S Food and Drug Administration (FDA) for targeted therapies for various types of cancers have significantly improved the market revenue. The study indicates, rapid development of targeted therapy small molecule drugs due to their high precision and effectiveness for cancer treatment will sustain revenues in the market through 2029. Fact.MR estimates, the global oncology small molecule drugs market to expand at an impressive CAGR of 6% through 2029. “Market players are focusing on robust R&D initiatives, product launches, and expanding their regional presence to stay ahead of competition,” says the Fact.MR analyst. Request a report sample to gain comprehensive insights at Key Takeaways United States expected to the highest as well as the fastest growing market for oncology small molecule drugs through 2029 In terms of drugs class, targeted therapy drugs to be the most lucrative segment Increased research and development activities across Japan to provide growth opportunities for market players in the region Oral oncology small molecule drugs to dominate the market over the forecast period Immunomodulating drugs are expected to emerge as a potential segment through 2021 Surging demand for the treatment of non-small cell lung cancer is likely to generate high revenues from the segment Tumor-specific cell-surface antigens are expected to contribute high revenue in the oncology small molecule drugs market through 2021 & beyond Prominent Drivers Increased R&D expenditure in the pharmaceutical and biopharmaceutical industry is expected to drive the demand of oncology small molecule drugs Rising demand for outsourcing clinical trial services and analytical testing may accelerate the growth of the market Rapid technological advancement for new and improved product development to drive the market growth through 2021 Key Restraints High cost of drug discovery and development is likely to restrict the growth of the market Stringent regulations for oncology small molecule drugs is expected to challenge the market growth Low production capability of oncology drugs may hamper the demand of oncology small molecule drugs market Discover more about the oncology small molecule drugs market with 215 figures, 53 data tables and the table of contents. Competitive Landscape Key market players listed by Fact.MR for global oncology small molecule drugs market includes Novartis AG, Genentech, Pfizer, AbbVie, Roche, Bayer, Genzyme Corporation (Sanofi), and Eli Lilly & Co. among others. According to the study, the market is expected to be consolidated. Prominent market players are orchestrating strategic collaboration with top bio-pharma companies to maintain their lead in the oncology small molecule drugs market. Robust R&D activities and new product launches are the key focus area to maintain their foothold in the industry. For instance, in April 2021, Exscientia, a leading Artificial Intelligence (AI)-driven pharma tech company, announced the launch of its first AI-designed molecule for immune-oncology to enter human clinical trials. The A2a receptor antagonist that is in development for adult patients with advanced solid tumors, was co-invented and developed through collaboration between Exscientia and Evotec, including application of Exscientia’s next generation 3-D evolutionary AI-design platform as part of Centaur Chemist®. Also, in January 2021, Nirogy Therapeutics Inc., a private bio-technology company developing novel small molecules to target cellular transporters, announced a drug delivery platform in conjunction with Santé Ventures and Sporos, with a closing of US$ 16.5 million to generate a pipeline of small-molecule drugs designed to target the solute carrier family of transporter proteins (SLCTs) embedded in cell membrane. Get Customization on this Report for Specific Research Solutions More Insights on the Oncology small molecule drugs Market Fact.MR offers an in-depth analysis on its latest market research report on global oncology small molecule drugs market. The report delivers detailed insights on the major growth drivers, trends, challenges and opportunities, the market is expected to prevail through 2021 and beyond. To gain a better perspective for the oncology small molecule drugs market scenario and ongoing trends, the market is segmented on the basis of drug class (chemotherapy drugs, immunomodulating drugs, targeted therapy drugs and hormonal therapy), indication (non-small cell lung cancer, renal cell carcinoma, breast cancer, prostate cancer, multiple myeloma, melanoma, lymphoma, leukemia and others), distribution channel (hospital pharmacies, retail pharmacies, specialty clinics, and online pharmacies), route of administration (oral and injectable) across major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa). Read More Trending Reports of Fact.MR Explore Fact.MR’s Coverage on the Healthcare Domain Oncology Biosimilars Market: A recent study by Fact.MR on the oncology biosimilars market offers an unbiased analysis on the opportunities and trends through 2021 and beyond. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the challenges, restraints, and opportunities for key market players along with key stakeholders and emerging players. Diuretic Drugs Market: Fact.MR gives a detailed assessment of Diuretic drugs market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study. Anticancer Drugs Market: Fact.MR delivers an in-depth analysis on global anticancer drugs market with the strategies and competitive landscape through 2021 and beyond. The key players’ market share data provided by the report given you a detailed insights on the shortcomings and forthcomings of the market for the forecast period. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Years after co-founding SINE-focused Karyopharm and stirring up controversy at MD Anderson, Ronald DePinho is helping uncloak a new biotech targeting solute carrier transporter proteins — and Karyopharm’s former head of chemistry is leading the charge. Nirogy Therapeutics emerged from stealth mode on Tuesday with a $16.5 million Series A round and plans to hit the clinic by 2022. The financing should be enough to carry the startup’s lead program, a small molecule lactate transport inhibitor, through Phase I, CEO Vincent Sandanayaka said. Sandanayaka said he first became intrigued by tumor metabolism while leading the chemistry unit at Karyopharm — another oncology company that DePinho helped start before joining MD Anderson. That biotech landed a Series A in 2010 for its work on selective inhibitors of nuclear export (SINE), and raised eyebrows last year when its multiple myeloma drug got approval from the FDA despite objections from 8 of the 13 experts on an outside panel. After co-founding Karyopharm, DePinho served a six-year tenure as president at MD Anderson, during which time the center reported operating losses of more than $460 million over 16 months and hundreds of staffers were laid off. He stepped down in 2017. But while many researchers in the space were going after intracellular targets, not many were working on solute carrier transporters — membrane-bound proteins that block or regulate metabolites like glucose, Sandanayaka said. Solute carrier transporter proteins (SLCTs) act as gatekeepers of important physiological functions, including nutrient uptake and metabolite disposal. The proteins are aberrantly altered in many diseases — but they’re difficult to isolate, and thus difficult to study. “If you take these transporters out of the membrane, like if you’re trying to isolate it, you may lose the functional state of the protein,” Sandanayaka said. Nirogy gets around the issue by using computational modeling. The CEO founded Nirogy in 2014 and reached out to DePinho in 2019, the same year the startup got some seed funding. Their lead program takes a two-pronged approach to fight cancer. Unlike normal cells, cancer cells consume large amounts of glucose, and excrete lactic acid into the tumor microenvironment through lactate transporters. This creates a hostile environment for immune cells to survive. But if that lactic acid isn’t released, it accumulates, causing the cell to die, Sandanayaka said. Nirogy’s candidate fights cancer cells by inhibiting them from expelling the lactate, while also boosting immune response. Sandanayaka believes this “one-two punch” is what differentiates it from Jnana Therapeutics, which struck an alliance with Roche in July to explore SLCT targets in immune-mediated and neurological diseases. That deal starts small at $40 million, but can add up to $1 billion if the pharma partner commits to developing the programs. “As you might imagine for a lot of drugs cancer cells develop resistance. So that’s part of the problem, it may be active initially, but then cancer cells develop a resistance… So, that is why we thought we want to have a multi-pronged approach to address this drug resistance,” Sandanayaka said. The startup plans to test the lactate inhibitor both as a monotherapy and combination therapy, and has done preclinical models in triple negative breast cancer, melanoma, and colorectal cancer, in combination with anti-PD1 and anti-CTLA4 immunotherapies. In addition to the lead program, Nirogy has a second transporter target in cancer and a third program in immunology. The tiny five-person company could grow to 15-20 people over the next few months, Sandanayaka said.

A brief rundown of who’s raking in cash in the biopharma world. TScan Therapeutics With $100 million in the pocket after a successful Series C, TScan is ready to bring two cancer therapies into the clinic. TScan is developing allogenic, off-the-shelf T cell cancer therapies based on the company’s T cell receptor (TCR) technology that target tumor antigens. INDs are anticipated soon for the two lead candidates aimed at hematological cancers – acute myeloid leukemia, myelodysplastic syndrome and T-cell acute lymphoblastic leukemia. “Recently, we have identified over 40 novel cancer targets from clinically active TCRs for development of multiplexed TCR-T cell therapies as part of our solid tumor program,” Southwell said. “Our goal is to continue to build a bank of clinically-active TCRs throughout 2021.” Plexium, Inc. Working in the new and exciting protein-degradation space, Plexium brought in more cash this week to target E3 ligases, the enzymes that drive recognition of protein targets. Extending its Series A from October 2019, the biotech completed a $35 million raise, bringing the cumulative total to $63 million. Working to drug the “undruggable” proteins, the first area of focus will be cancer and neurodegenerative diseases. The funds will accelerate the monovalent degraders through preclinical development and support Plexium’s research efforts. "The field of protein degradation is one of the most rapidly advancing and promising categories in biotech today. Plexium is breaking new ground in the field with its novel DELPhe platform which provides researchers with the right tools to pick a target and selectively degrade it using a small molecule,” said Plexium’s new addition to the company’s board, Mike Grey. Nirogy Therapeutics While many new biotechs are focused on cutting-edge gene therapies, there’s still a seat available at the table for small molecule makers too. Boston-based Nirogy proves that by launching this week with a $16.5 million Series A to fight cancer with a largely unexplored target. Nirogy’s drugs go after the solute carrier family of transporter proteins (SLCTs). These proteins are embedded in the cell membrane and act as gatekeepers of a number of functions, including nutrient uptake and metabolite disposal. Due to the complex structures of SLCTs, they’ve not yet been effectively targeted. “Our team’s strength in computational modeling, medicinal chemistry and cancer biology has enabled us to overcome the challenge of drugging these critical untapped targets,” said the company’s CEO. Success in this area could yield over 450 druggable targets and open new treatment options for life-threatening diseases. The lead program should be ready to take to the clinic in 2022. MIVI Neuroscience, Inc. This stroke-focused medical device company scooped up $35 million in a Series B to fund clinical trials for MIVI’s products. Specializing in products to improve patient outcomes for neurointerventional procedures, the company’s lead devices are DAISe Thrombectomy System and Q Aspiration System. The DAISe system is designed to improve clot retrieval while reducing the risk of clot loss with a delivery similar to a stent-retriever. It’s currently in development and not yet for sale. Funds will also be used to expand MIVI’s commercial operations outside the US and drive the development of new devices. "The mechanical thrombectomy market is expected to grow substantially over the coming years. This investment ensures that MIVI is well positioned to capitalize on this tremendous opportunity and we couldn't be more excited about our future,” said board chairman Fred Moll. Ambulero, Inc. Partnering with Orphinic Scientific as an investor, Ambulero took in $5.5 million to advance its gene therapies for vascular diseases. As part of the deal, the two companies formed a Polish subsidiary to lead clinical testing in Europe for a rare vascular disease that is more common in parts of Central and Eastern Europe. “We are excited to participate in a global development of Ambulero’s breakthrough gene therapy that has a potential to reduce risk of limb ulcers and amputation in patients affected by vascular diseases,” said Dr. Artur Plonowski, Partner and CMO at Orphinic. Companies with IPO Announcements More companies have been jumping on the IPO bandwagon than ever. As Wugen CEO John McKearn told BioSpace, he’s wanting to take the company public “as fast as we can move.” Clearly many biotechs are – check out the list of recent IPO news here.